Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [Phase 1]
Phase 1 study of MK-2206 in pediatric patients with recurrent or refractory solid tumors or leukemias has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…
-
CLINICAL_TRIALS research · 2013-12-18Clinical Trial Update: Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Beta Alethine for Waldenström's macroglobulinemia is reported. Sponsor is LifeTime Pharmaceuticals and…
-
CLINICAL_TRIALS research · 2013-12-18Clinical Trial Update: Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia
This clinical trial update describes collecting stem cells from patients with Waldenström macroglobulinemia. The current trial status is lis…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma [Phase 3]
A Phase 3 trial evaluating chlorambucil versus fludarabine as first-line therapy for previously untreated Waldenström macroglobulinemia, spl…
-
CLINICAL_TRIALS trial_result · 2013-08-16Clinical Trial Update: Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating Rituximab for Waldenström macroglobulinemia has completed. The study was conducted by the Eastern Cooperative Onc…
-
CLINICAL_TRIALS trial_result · 2013-08-02Clinical Trial Update: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia [Phase 1]
A Phase 1 dose-escalation study of MLN0128 in relapsed or refractory multiple myeloma and Waldenström macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2013-07-02Clinical Trial Update: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies [Phase 1]
A Phase 1 dose-escalation study of TAK-901 in subjects with advanced hematologic malignancies; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-26Clinical Trial Update: Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial of Dolastatin 10 in patients with indolent non-Hodgkin lymphoma, Waldenström's macroglobulinemia, or chronic lymphocytic leuke…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
This clinical trial update notes the completion of Phase 1 and Phase 2 studies of oblimersen (Genasense) in patients with relapsed or refrac…
-
CLINICAL_TRIALS trial_result · 2013-05-17Clinical Trial Update: Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating bortezomib in Waldenström's macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-12Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial update investigating rituximab with combination chemotherapy for newly diagnosed Waldenström's macroglobulinemia; the study is…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Yttrium-90 ibritumomab tiuxetan in combination with rituximab for post-transplant lymphoproliferative disorder …
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]
A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-14Clinical Trial Update: SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of SB-715992 in patients with metastatic or unresectable solid tumors and various Hodgkin's and non-Hodgkin's lymphomas has be…
-
CLINICAL_TRIALS trial_result · 2013-01-08Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 1]
Phase 1 trial of Yttrium-90 ibritumomab tiuxetan (Zevalin) for Waldenström's macroglobulinemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-08Clinical Trial Update: Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating rituximab in combination with fludarabine for Waldenström's macroglobulinemia has completed.
-
CLINICAL_TRIALS withdrawal · 2013-01-08Clinical Trial Update: Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial of alemtuzumab for Waldenström's macroglobulinemia has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-12-21Clinical Trial Update: Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia [Phase 2]
Phase II trial of Campath-1H (alemtuzumab) for Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2012-08-09Clinical Trial Update: Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood [Phase 2]
This entry summarizes a Phase 2 trial evaluating low-intensity conditioning followed by allogeneic stem cell transplantation for patients wi…
-
CLINICAL_TRIALS trial_result · 2012-04-30Clinical Trial Update: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia [Phase 2]
Phase II trial evaluating ofatumumab in Waldenström macroglobulinemia; the study has completed and results were posted in 2012.